Inovio Pharmaceuticals (INO) Q1 2026 earnings summary

Executive summary

• INO-3107 for RRP is under FDA Accelerated Approval review with a PDUFA date of October 30, 2026; mid-cycle review completed with no new significant issues, but eligibility for accelerated approval remains under discussion.

• Commercial launch preparations for INO-3107 are advancing, including market research, pricing strategy, and engagement with key partners for distribution and patient support.

• Pipeline progress includes a collaboration with Akeso and Dana-Farber for glioblastoma, and advancement of next-generation DNA-encoded protein (dPROT) technology for rare diseases such as hemophilia A, Fabry disease, and hypophosphatasia.

• No product revenues; operations funded by equity offerings, grants, and collaborations.

Financial highlights

• Q1 2026 net loss was $19.7 million ($0.28 per share), unchanged from Q1 2025, with per-share loss improved due to increased share count.

• Operating expenses for Q1 2026 were $21.9 million, down 13% year-over-year, with R&D expenses at $14.1 million and G&A at $7.9 million.

• Cash, cash equivalents, and short-term investments totaled $37.7 million as of March 31, 2026, excluding $16 million from an April 2026 equity offering.

• April 2026 public equity offering raised $16 million, extending cash runway into Q1 2027.

• No outstanding debt; accumulated deficit reached $1.8 billion as of March 31, 2026.

Outlook and guidance

• Cash runway, including April 2026 equity raise, is projected to last into Q1 2027, beyond the INO-3107 PDUFA date.

• No additional capital raises included in current projections, but further financing will be needed for continued operations and product development.

• Commercial launch of INO-3107 anticipated if approved, with most of the RRP market opportunity remaining due to low penetration by the first entrant.

• Awaiting FDA response on INO-3107, with late-cycle review meeting scheduled for Q3 2026.